Answers are grounded in this paper and cite their sources.
Alzheimer’s disease (AD) continues to pose a major therapeutic challenge, primarily due to the restricted ability of drugs to traverse the blood-brain barrier (BBB). Solid lipid nanoparticles have gained attention as effective nanocarriers capable of addressing this limitation, thanks to their favourable biocompatibility, capacity to improve drug stability, and potential for sustained drug release. This research investigates the application of the QbD framework in formulating SLNs aimed at enhancing BBB penetration and achieving targeted drug delivery for AD management. The finalized SLN formulation exhibited significantly improved permeability across the BBB, as evidenced by both in-vitro and in-vivo assessments. These findings suggest a promising advancement in AD therapeutics. Moreover, the use of QbD principles in the development process contributes to the creation of consistent, high-quality nanoparticle systems that meet current regulatory standards for nanomedicine.
No takes yet. Share an insight, caveat, or question.
Bala et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: